Wish to keep on prime of the science and politics driving biotech right this moment? Enroll to get our biotech publication in your inbox.
Good morning. We’ve bought extra developments with Sarepta right this moment. My colleagues bought unique feedback from a senior FDA official — learn on for what the official stated.
The necessity-to-know this morning
- Roche is following its companion Sarepta Therapeutics and stopping shipments of the Duchenne muscular dystrophy gene remedy Elevidys in some international locations, amid rising security considerations surrounding the therapy.
- An experimental oral therapy from Abivax helped ease signs at compelling charges in sufferers with a sort of bowel illness in a pair of Section 3 trials. Shares of the Paris-based drugmaker are hovering this morning.
Sean Parker and ARCH launch a most cancers biotech
A brand new biotech referred to as Dispatch Bio launched right this moment with the purpose of growing a brand new, common strategy to attempt to deal with any most cancers utilizing immunotherapy.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
